对高病毒载量慢性乙肝初治患者血清Mig、RANTES及肝纤维化指标表达的影响

Abstract
Figure/Table
References (168)
Related Citation (15)

Download: PDF (367 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of peginterferon α-2a combined with Tenofovir Disoproxil on serum monokine induced by interferon-γ (Mig), regulated upon activation normal T-cell expressed and secreted factors (RANTES) and indicators of liver fibrosis in newly diagnosed chronic hepatitis B patients with high viral load. Methods A total of 168 patients with HBeAg-positive chronic hepatitis B treated in West China-Guang′an Hospital, Sichuan University from June 2016 to December 2017 were selected and divided into the experimental group and the control group by random number table method, with 84 cases in each group. The patients in the control group received monotherapy with Tenofovir Disoproxil, on basis of which, the patients in the experimental group were added with peginterferon α-2a, and both groups were treated for 6 months. The therapeutic effects and serum Mig, RANTES and indicators of liver fibrosis were compared between the two groups. Results The HBV DNA negative rate, HbeAg negative rate and HBeAg seroconversion rate in the experimental group were significantly higher than those in the control group (P ＜ 0.05). After treatment, the Mig and RANTES levels in the two groups were significantly lower than those before treatment (P ＜ 0.05), and the Mig and RANTES levels in the experimental group were significantly lower than those in the control group (P ＜ 0.05). After treatment, the indicators of liver fibrosis (hyaluronic acid, laminin, collagen-Ⅳ and procollagen-Ⅲ) in the two groups were significantly lower than those before treatment (P ＜ 0.05), and the levels of indicators of liver fibrosis in the experimental group were significantly lower than those in the control group (P ＜ 0.05). Conclusion Pegylated interferon α-2a combined with Tenofovir Disoproxil can significantly reduce the levels of serum Mig and RANTES in patients with hepatitis B, and effectively improve the indicators of liver fibrosis in patients with hepatitis B, which is worthy of clinical promotion.

Key words： Hepatitis B Liver fibrosis Monokine induced by interferon-γ Regulated upon activation normal T-cell expressed and secreted factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiao

Cite this article:

LI Xiao. Effect of peginterferon α-2a and Tenofovir Disoproxil on the expression of serum Mig, RANTES and indicators of hepatic fibrosis in newly diagnosed chronic hepatitis B patients with high viral load[J]. 中国医药导报, 2020, 17(1): 165-.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I1/165

[1] Niederau C. Chronic hepatitis B in 2014：Great therapeutic progress，large diagnostic deficit [J]. WJG，2014，20（33）：11595-11617.
[2] Tang CM，Yau TO，Yu J. Management of chronic hepatitis B infection：Current treatment guidelines，challenges，and new developments [J]. WJG，2014，20（20）：6262-6278.
[3] Havens PL，Kiser JJ，Stephensen CB，et al. Association of Higher Plasma Vitamin D Binding Protein and Lower Free Calcitriol Levels with Tenofovir Disoproxil Fumarate Use and Plasma and Intracellular Tenofovir Pharmacokinetics：Cause of a Functional Vitamin D Deficiency? [J]. Antimicrob Agents Chemother，2013，57（11）：5619-5628.
[4] Siberry GK，Jacobson DL，Kalkwarf HJ，et al. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy [J]. Clin Infect Dis，2015，61（6）：996-1003.
[5] Korkmaz P，Usluer G，Ozgunes I，et al. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients [J]. North Clin Istanb，2014，1（1）：26-32.
[6] 汤波，韦佳佳，徐丙发，等.STAT1修饰对干扰素抗乙肝病毒作用影响的研究进展[J].安徽医科大学学报，2017， 14（4）：615-618.
[7] 肖瑶，王建青，祝亚文，等.恩替卡韦联合聚乙二醇干扰素抗乙肝病毒疗效观察[J].中国药师，2017，21（8）：1420-1422.
[8] 邓卫平，马德强，郑红梅，等.百令胶囊辅助恩替卡韦治疗干扰素无应答乙肝疗效观察[J].现代中西医结合杂志，2017，7（36）：4009-4012.
[9] 邹红霞，倪丽娜，郝军.长效干扰素治疗慢性乙型肝炎e抗原阴性患者疗效研究[J].国际病毒学杂志，2013，12（6）：270-272.
[10] 尚鹏程，许娇，裴晓方.慢乙肝和慢重肝患者趋化因子的表达差异及干扰素治疗后的变化[J].现代预防医学，2017，21（5）：882-885.
[11] 张耿林，徐士丞，朱翔，等.高表达CCL20对乙肝相关慢加急性肝衰竭患者的影响[J].中山大学学报：医学科学版，2016，36（5）：692-696.
[12] 汪旭，董科，俞小炯，等.肝癌组织中白细胞分化抗原90和趋化因子受体4的表达与术后早期复发的关系[J].中国老年学杂志，2017，28（2）：399-401.
[13] 方良春，管世鹤，周强，等.慢性乙型肝炎患者趋化因子Mig表达水平的研究[J].国际检验医学杂志，2016，10（9）：1164-1165.
[14] 贾华锋.乙肝抗纤汤联合干扰素治疗乙型肝炎后肝纤维化疗效观察[J].现代中西医结合杂志，2016，25（6）：631-633.
[15] 顾生旺，刘欢，蒋兆荣，等.普通干扰素与聚乙二醇干扰素加重肝纤维化的临床观察[J].肝脏，2017，22（12）：1126-1128.
[16] 夏六均，赵维群，黄浩.替诺福韦酯联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎临床疗效及影响因素分析[J].实用医院临床杂志，2018，15（4）：210-213.
[17] 杨艳，张新.慢性HBV感染者获得病毒学应答后肝纤维化/肝硬化逆转因素的分析[J].临床肝胆病杂志，2018， 34（7）：182-185.
[18] 林志鹏，苏密龙，苏智军，等.替诺福韦联合聚乙二醇干扰素α2a注射液治疗耐药慢性乙型病毒性肝炎患者的临床研究[J].中国临床药理学杂志，2018，34（2）：108-110.
[19] 史罗明，周根法，孙冬林.聚乙二醇干扰素-α-2a治疗血清低水平HBsAg阳性的慢性乙型肝炎患者临床结局预测研究[J].实用肝脏病杂志，2018，21（4）：565-568.